Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Ford

Showing results (821-830 of 1,828) with videos related to

Pageof 183
Sort By:
Medical Physics|October 1, 2010
A method for optimizing LINAC treatment geometry for volumetric modulated arc therapy of multiple brain metastasesJun Kang, Eric C Ford, Koren Smith, et al.
FEBS Letters|January 13, 1992
Analysis of the structure of photosystem I in cyanobacterial thylakoid membranesA Hefti, R C Ford, M Miller, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2022
Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome. Authors' replyVivek C Goodoory, Cho Ee Ng, Christopher J Black, et al.
Acta Neurologica Scandinavica|December 15, 2004
Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year dataK P Johnson, C C Ford, R P Lisak, et al.
Chemical Communications (Cambridge, England)|June 25, 2004
Low temperature NO disproportionation by Mn porphyrin. Spectroscopic characterization of the unstable nitrosyl nitrito complex MnIII(TPP)(NO)(ONO)Garik G Martirosyan, Arsen S Azizyan, Tigran S Kurtikyan, et al.
Sub-Cellular Biochemistry|September 23, 2022
ATP-Binding Cassette Transporters: Snap-on Complexes?Iqra Younus, Sofia Kochkina, Cheri C Choi, et al.
Alimentary Pharmacology & Therapeutics|September 28, 2022
Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease-authors' replyKeeley M Fairbrass, P John Hamlin, David J Gracie, et al.
Alimentary Pharmacology & Therapeutics|May 2, 2022
Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United KingdomVivek C Goodoory, Cho Ee Ng, Christopher J Black, et al.
Alimentary Pharmacology & Therapeutics|February 15, 2022
Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndromeVivek C Goodoory, Cho Ee Ng, Christopher J Black, et al.
JAMA Pediatrics|September 23, 2018
Prevalence of Adverse Childhood Experiences From the 2011-2014 Behavioral Risk Factor Surveillance System in 23 StatesMelissa T Merrick, Derek C Ford, Katie A Ports, et al.
Pageof 183

Showing results (821-830 of 1,828) with videos related to

Sort By:
Pageof 183
Medical Physics|October 1, 2010
A method for optimizing LINAC treatment geometry for volumetric modulated arc therapy of multiple brain metastasesJun Kang, Eric C Ford, Koren Smith, et al.
FEBS Letters|January 13, 1992
Analysis of the structure of photosystem I in cyanobacterial thylakoid membranesA Hefti, R C Ford, M Miller, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2022
Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome. Authors' replyVivek C Goodoory, Cho Ee Ng, Christopher J Black, et al.
Acta Neurologica Scandinavica|December 15, 2004
Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year dataK P Johnson, C C Ford, R P Lisak, et al.
Chemical Communications (Cambridge, England)|June 25, 2004
Low temperature NO disproportionation by Mn porphyrin. Spectroscopic characterization of the unstable nitrosyl nitrito complex MnIII(TPP)(NO)(ONO)Garik G Martirosyan, Arsen S Azizyan, Tigran S Kurtikyan, et al.
Sub-Cellular Biochemistry|September 23, 2022
ATP-Binding Cassette Transporters: Snap-on Complexes?Iqra Younus, Sofia Kochkina, Cheri C Choi, et al.
Alimentary Pharmacology & Therapeutics|September 28, 2022
Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease-authors' replyKeeley M Fairbrass, P John Hamlin, David J Gracie, et al.
Alimentary Pharmacology & Therapeutics|May 2, 2022
Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United KingdomVivek C Goodoory, Cho Ee Ng, Christopher J Black, et al.
Alimentary Pharmacology & Therapeutics|February 15, 2022
Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndromeVivek C Goodoory, Cho Ee Ng, Christopher J Black, et al.
JAMA Pediatrics|September 23, 2018
Prevalence of Adverse Childhood Experiences From the 2011-2014 Behavioral Risk Factor Surveillance System in 23 StatesMelissa T Merrick, Derek C Ford, Katie A Ports, et al.
Pageof 183